Last reviewed · How we verify

NCT03584607

Insulin- and Glucose Metabolism in Pulmonary Arterial Hypertension

Completed Last updated 27 January 2020
What this trial tests

trial in Insulin Resistance in 10 participants. Completed in 11 February 2019.

Timeline
20 December 2017
Primary endpoint
11 February 2019
11 February 2019

Quick facts

Lead sponsorMedical University of Graz
StatusCompleted
Study typeOBSERVATIONAL
Enrollment10
Start date20 December 2017
Primary completion11 February 2019
Estimated completion11 February 2019
Sites1 location across Austria

Conditions studied

Sponsor

Medical University of Graz

Who can join

Adults 18 to 90, any sex, with Insulin Resistance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Insulin resistance is a key mechanism in metabolic disorders, which has also been implicated in the development of pulmonary hypertension. In this pilot study, the investigators´ goal is to directly determine insulin sensitivity in idiopathic pulmonary arterial hypertension patients and to compare the results with data from healthy controls.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. 43. Jahrestagung der Österreichischen Gesellschaft für Pneumologie. 3. Jahrestagung der Österreichischen Gesellschaft für Thoraxchirurgie
    · 2019

Verify or expand the search:

Other recruiting trials for Insulin Resistance

Currently open trials in the same condition.

Other Medical University of Graz trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03584607.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing